News tagged with atorvastatin
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.
Diabetes May 23, 2013 | not rated yet | 0
(HealthDay)—Different types and doses of statins seem to correlate with distinct risks of developing new-onset diabetes mellitus (DM), according to a meta-analysis published in the April 15 issue of The Am ...
Cancer Apr 11, 2013 | not rated yet | 0
Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date ...
Cancer Apr 07, 2013 | 1 / 5 (1) | 0
(HealthDay News) —Prescription drug prices at U.S. pharmacies can vary widely, and failing to shop around could result in people overpaying by as much as $100 or more a month on average, depending on the ...
Medications Mar 28, 2013 | not rated yet | 0
Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalised for acute kidney injury (AKI), compared with those taking low potency statins, a paper published today in BMJ sugges ...
Cardiology Mar 19, 2013 | 5 / 5 (1) | 1
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research ...
Cardiology Mar 11, 2013 | not rated yet | 0
Problem-plagued Ranbaxy Pharmaceuticals Inc. has halted production of generic cholesterol drug Lipitor while it investigates how tiny glass particles got into the ingredients used for dozens of batches of the drug that were ...
Medications Nov 30, 2012 | not rated yet | 0
(HealthDay)—People who exercise along with taking statins to lower their high cholesterol levels can dramatically reduce their risk of dying, a large new study suggests.
Cardiology Nov 28, 2012 | not rated yet | 1 |
(AP)—Ranbaxy Pharmaceuticals Inc. has recalled dozens of lots of its generic version of cholesterol drug Lipitor because some may contain tiny glass particles, the latest in a string of manufacturing deficiencies that once ...
Medications Nov 23, 2012 | not rated yet | 0
(HealthDay)—Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) ...
Medical research Nov 02, 2012 | 5 / 5 (1) | 0
(HealthDay) -- The widely used class of cholesterol-lowering medications known as statins may help elderly patients with high blood pressure avoid developing atrial fibrillation, a heart rhythm abnormality ...
Cardiology May 10, 2012 | not rated yet | 0 |
(HealthDay) -- Administration of REGN727, a monoclonal antibody to proprotein convertase subtilisin/kexin 9 (PCSK9), significantly reduces low-density lipoprotein (LDL) cholesterol levels, according to the ...
Cardiology Mar 22, 2012 | 3 / 5 (1) | 1 |
US officials sought a "groundbreaking" injunction against Indian drug giant Ranbaxy on Wednesday, saying the maker of the first generic version of cholesterol-lowering Lipitor has failed to meet US safety guidelines.
Medications Jan 26, 2012 | not rated yet | 0
In the United States, the cost paid for statins (drugs to lower cholesterol) in people under the age of 65 who have private insurance is approximately 400 percent higher than comparable costs paid by the government in the ...
Medications Jan 05, 2012 | 3.7 / 5 (3) | 12
Sales of cholesterol blockbuster Lipitor plunged by half barely a week after the world's top-selling drug got its first U.S. generic competition, new data show.
Medications Dec 20, 2011 | not rated yet | 3
Atorvastatin (INN) ( /əˌtɔrvəˈstætən/), sold by Pfizer under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.
Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2008 sales of US$12.4 billion, Lipitor was the top-selling branded pharmaceutical in the world. U.S. patent protection was scheduled to expire in June 2011. However, Pfizer made an agreement with Ranbaxy Laboratories to delay the generic launch in the U.S. until November 30, 2011.
For more information about Atorvastatin, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.